DOKTOR FALK FARMA GMBKH, PREDSTAVITELSTVO
Clinical Trials
330
Trial Phases
4 Phases
Drug Approvals
18
Drug Approvals
Ursodeoxycholic Acid Capsules
- Product Name
- 优思弗
- Approval Number
- 国药准字HJ20181059
- Approval Date
- Oct 11, 2024
Mesalazine Enteric-coated Tablets
- Product Name
- 莎尔福
- Approval Number
- 国药准字HJ20171358
- Approval Date
- Sep 10, 2024
Ursodeoxycholic Acid Oral Suspension
- Product Name
- 熊去氧胆酸口服混悬液
- Approval Number
- 国药准字HJ20240072
- Approval Date
- Jul 16, 2024
Mesalazine Enteric-coated Tablets
- Product Name
- 莎尔福
- Approval Number
- 国药准字HJ20202002
- Approval Date
- Jul 28, 2020
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (250 trials with phase data)• Click on a phase to view related trials
Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC)
- First Posted Date
- 2025-03-20
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 120
- Registration Number
- NCT06886360
Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 308
- Registration Number
- NCT06596252
- Locations
- 🇺🇸
Dr. Falk Investigational Site, Harlingen, Texas, United States
🇪🇸Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso, Spain
Different Doses of Naronapride Vs. Placebo in Gastroparesis
- First Posted Date
- 2022-11-18
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 320
- Registration Number
- NCT05621811
- Locations
- 🇺🇸
Dr Falk Investigational Site, Harlingen, Texas, United States
🇧🇪University of Leuven, Leuven, Belgium
Mesalazine Oral Suspension in Active Eosinophilic Esophagitis
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 5
- Registration Number
- NCT05488405
- Locations
- 🇨🇭
Universitätsspital Zürich, Zürich, Switzerland
Different Doses of ZED1227 vs. Placebo in NAFLD
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 186
- Registration Number
- NCT05305599
- Locations
- 🇩🇪
Department of Medicine, University Medical Centre, Johannes Gutenberg University Mainz, Mainz, Rheinland-Pfalz, Germany
- Prev
- 1
- 2
- 3
- 4
- 5
- 8
- Next
News
Breakthrough Therapies Set to Transform Eosinophilic Esophagitis Treatment Landscape
The eosinophilic esophagitis (EoE) market is projected to grow from $1.8 billion in 2023 to a significantly higher value by 2034, driven by increased disease awareness and healthcare spending.